金达莱（688057）披露对外投资事项问询函回复，1月7日股价下跌0.16%

Core Viewpoint - Jindalai (688057) is making strategic investments in JiCi Medical and Zhongke Hongtai to enhance its presence in the fields of autologous cell technology and vascular interventional surgical robots, respectively [1] Group 1: Stock Performance - As of January 7, 2026, Jindalai's stock closed at 12.45 yuan, down 0.16% from the previous trading day, with a total market capitalization of 3.436 billion yuan [1] - The stock opened at 12.54 yuan, reached a high of 12.58 yuan, and a low of 12.42 yuan, with a trading volume of 15.0675 million yuan and a turnover rate of 0.44% [1] Group 2: Investment Announcements - Jindalai plans to invest 280 million yuan in JiCi Medical, acquiring a 34.00% stake; JiCi Medical focuses on the research and development of autologous cell technology and holds multiple invention patents, led by Professor Hu Min [1] - The investment in Zhongke Hongtai aims to establish a foothold in the vascular interventional surgical robot sector, with related products currently undergoing special review procedures for national innovative medical devices [1] - The announcement also details the purpose of the investments, valuation basis, synergistic effects, and risk management measures [1]